Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
2014
Background
Recently, glucagon-like peptide-1 (GLP-1)-based therapy, including dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, has emerged as one of the most popular anti-diabetic therapies. Furthermore, GLP-1-based therapy has attracted increased attention not only for its glucose-lowering ability, but also for its potential as a tissue-protective therapy. In this study, we investigated the vascular-protective effect of the DPP-4 inhibitor, linagliptin, using vascular smooth muscle cells (VSMCs).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
37
References
42
Citations
NaN
KQI